We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$111B
AUM Growth
+$1.46B
Cap. Flow
+$2.6B
Cap. Flow %
2.33%
Top 10 Hldgs %
23.97%
Holding
4,345
New
253
Increased
2,150
Reduced
1,535
Closed
239

Sector Composition

Rank Sector Weight
1 Technology 14.74%
2 Financials 9%
3 Healthcare 8.22%
4 Consumer Discretionary 6.53%
5 Industrials 6.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MCA
3526
DELISTED
BLACKROCK MUNIYIELD CALIFORNIA QUALITY FUND, INC
MCA
$253K ﹤0.01%
15,934
-840
-5% -$13.4K
EWS icon
3527
iShares MSCI Singapore ETF
EWS
$1.16B
$252K ﹤0.01%
11,079
-200
-2% -$4.65K
OTEX icon
3528
Open Text
OTEX
$6.02B
$252K ﹤0.01%
5,167
+766
+17% +$40K
SIGI icon
3529
Selective Insurance
SIGI
$5.59B
$252K ﹤0.01%
3,339
+7
+0.2% +$564
FOLD
3530
DELISTED
Amicus Therapeutics
FOLD
$250K ﹤0.01%
26,228
-8,389
-24% -$85.8K
GSHD icon
3531
Goosehead Insurance
GSHD
$2.39B
$250K ﹤0.01%
+1,639
New +$221K
ELF icon
3532
e.l.f. Beauty
ELF
$5.43B
$248K ﹤0.01%
8,550
+775
+10% +$22.2K
OPCH icon
3533
Option Care Health
OPCH
$3.61B
$248K ﹤0.01%
+10,205
New +$237K
CCLP
3534
DELISTED
CSI Compressco LP
CCLP
$248K ﹤0.01%
137,931
+29,038
+27% +$43.5K
BTAI icon
3535
BioXcel Therapeutics
BTAI
$34.9M
$247K ﹤0.01%
508
+55
+12% +$24.2K
FELE icon
3536
Franklin Electric
FELE
$4.68B
$247K ﹤0.01%
3,089
+279
+10% +$22.9K
ZLAB icon
3537
Zai Lab
ZLAB
$2.92B
$247K ﹤0.01%
2,346
-674
-22% -$96.8K
ANIX icon
3538
Anixa Biosciences
ANIX
$109M
$246K ﹤0.01%
51,550
-2,506
-5% -$11.3K
IAGG icon
3539
iShares Core International Aggregate Bond Fund
IAGG
$11.4B
$246K ﹤0.01%
4,475
-365
-8% -$20.3K
TNET icon
3540
TriNet
TNET
$3.22B
$246K ﹤0.01%
+2,604
New +$223K
SRC
3541
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
$246K ﹤0.01%
5,346
-448
-8% -$22.3K
CAF
3542
Morgan Stanley China A Share Fund
CAF
$327M
$245K ﹤0.01%
11,664
-12,022
-51% -$257K
EVGO icon
3543
EVgo
EVGO
$519M
$245K ﹤0.01%
+30,060
New +$303K
PBI icon
3544
Pitney Bowes
PBI
$2.28B
$245K ﹤0.01%
33,938
+12,934
+62% +$101K
SLG icon
3545
SL Green Realty
SLG
$4.08B
$245K ﹤0.01%
3,464
-1,062
-23% -$77.5K
FCT
3546
DELISTED
First Trust Senior Floating Rate Income Fund II
FCT
$243K ﹤0.01%
19,865
-6,658
-25% -$82.5K
MPC icon
3547
CALL
Marathon Petroleum
MPC
$100B
$243K ﹤0.01%
111,500
-3,200
-3% -$184K
SCHZ icon
3548
Schwab US Aggregate Bond ETF
SCHZ
$10.6B
$243K ﹤0.01%
+8,972
New +$246K
JEQ
3549
DELISTED
abrdn Japan Equity Fund
JEQ
$242K ﹤0.01%
24,818
KURE icon
3550
KraneShares MSCI All China Health Care Index ETF
KURE
$107M
$242K ﹤0.01%
6,460

Similar funds

Raymond James & Associates's Q3 2021 Portfolio in Review

As of Q3 2021, Raymond James & Associates held 4,345 positions worth $111B, up 1.3% from $110B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2021 filing shows 253 new, 2,150 increased, 1,535 reduced and 239 closed positions. Its largest new stake was GXO Logistics: 224,392 shares worth $17.6M. The largest sale was iShares Core S&P Mid-Cap ETF, an estimated $358M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2021 buy was GXO Logistics: 224,392 shares worth $17.6M.
  • Raymond James & Associates added most to Vanguard Morningstar Mid-Cap ETF in Q3 2021, an estimated $569M increase.
  • Raymond James & Associates's biggest Q3 2021 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $358M.
  • Raymond James & Associates fully exited Invesco S&P 500 Equal Weight Energy ETF in Q3 2021, selling an estimated $9.16M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $111B portfolio in Q3 2021.
  • Raymond James & Associates opened 253 new positions and closed 239 in Q3 2021.
  • Raymond James & Associates's portfolio value rose 1.3% quarter-over-quarter to $111B.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.